Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
Oculis will present late-breaking Phase 2 ACUITY biomarker analyses of Privosegtor at the joint ACTRIMS-ECTRIMS meeting in Toronto on October 22, 2026. The new translational data evaluate plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation in acute optic neuritis, presented by principal investigator Professor Céline Louapre. Privosegtor holds FDA Breakthrough Therapy and EMA PRIME designations, with two registrational PIONEER trials ongoing and an IND planned for acute MS relapses.
Key figures
- Drug Name
- Privosegtor
- Phase Of Trial
- Phase 2
- R and d day
- 2026-12-08
- Presentation id
- P1507
- Presentation date
- 2026-10-22
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.